Clinical Trial Update: CyBeR Association in Relapsed/Refractory DLBCL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on the CyBeR association for relapsed/refractory diffuse large B-cell lymphoma, with current status listed as unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Snippet

Sponsor: University Hospital, Caen | Conditions: Diffuse Large B Cell Lymphoma | Phase 2 | Status: UNKNOWN